source
- #ADA26: AstraZeneca's GLP-1 pill cuts weight by 10.5% after six monthsThe race to be third to market with an obesity pill has a number of contenders, including Roche, Pfizer and Structure Therapeutics. On Monday, AstraZeneca set out its own stall with data on a pill ...Endpoints · 1mo ago↗ source
- STAT+: AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trialsAstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.STAT · 1mo ago↗ source
- City banks nearly $100M for next-gen RNAi drugsCo-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An experimental therapy for Stargardt disease could soon follow.